Can you provide the average price target for CVS HEALTH CORP stock?
33 analysts have analysed CVS and the average price target is 95.66 USD. This implies a price increase of 14.85% is expected in the next year compared to the current price of 83.29.
NYSE:CVS • US1266501006
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CVS HEALTH CORP (CVS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-15 | Baird | Maintains | Outperform -> Outperform |
| 2026-03-31 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-03-12 | Bernstein | Upgrade | Market Perform -> Outperform |
| 2026-01-28 | Argus Research | Maintains | Buy -> Buy |
| 2026-01-27 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-17 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-12-12 | Bernstein | Maintains | Market Perform -> Market Perform |
| 2025-12-10 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-10 | UBS | Maintains | Buy -> Buy |
| 2025-12-10 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-10 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-10 | Baird | Maintains | Outperform -> Outperform |
| 2025-12-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-10 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-12-05 | Bernstein | Maintains | Market Perform -> Market Perform |
| 2025-11-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-03 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-30 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-30 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-30 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-24 | UBS | Maintains | Buy -> Buy |
| 2025-10-14 | Goldman Sachs | Initiate | Buy |
| 2025-10-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-09 | Mizuho | Maintains | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 357.776B 10.95% | 372.809B 4.20% | 402.067B 7.85% | 409.251B 1.79% | 428.451B 4.69% | 448.742B 4.74% | 471.704B 5.12% | 492.51B 4.41% | 511.522B 3.86% | 547.671B 7.07% | 586.117B 7.02% | |
| EBITDA YoY % growth | N/A 0.50% | N/A -27.63% | N/A 15.92% | 18.039B 5.49% | 19.941B 10.54% | 21.958B 10.11% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 15.086B -7.39% | 10.038B -33.46% | 10.502B 4.62% | 15.405B 46.69% | 17.152B 11.34% | 19.105B 11.39% | 21.418B 12.11% | 23.063B 7.68% | N/A | N/A | N/A | |
| Operating Margin | 4.22% | 2.69% | 2.61% | 3.76% | 4.00% | 4.26% | 4.54% | 4.68% | N/A | N/A | N/A | |
| EPS YoY % growth | 8.74 0.46% | 5.42 -37.99% | 6.75 24.54% | 7.24 7.26% | 8.26 14.05% | 9.49 14.89% | 10.58 11.49% | 11.61 9.75% | 12.44 7.20% | 13.77 10.63% | 15.07 9.46% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.23 -1.11% | 1.81 -0.20% | 1.83 14.53% | 1.37 25.77% | 2.52 13.28% | 2.10 16.48% | 2.06 12.40% | 1.66 20.84% | 2.91 15.46% | 2.48 17.67% | 2.38 15.31% | 1.89 13.93% |
| Revenue Q2Q % growth | 96.153B 1.65% | 100.847B 1.95% | 104.606B 1.69% | 107.887B 2.08% | 100.402B 4.42% | 105.768B 4.88% | 110.104B 5.26% | 113.284B 5.00% | 106.246B 5.82% | 111.252B 5.18% | 115.946B 5.31% | 119.591B 5.57% |
| EBITDA Q2Q % growth | 5.073B 17.19% | 4.485B 15.33% | 4.506B 17.93% | 3.592B 14.83% | 5.763B 13.60% | 5.108B 13.89% | 4.727B 4.90% | 4.079B 13.56% | 6.355B 10.27% | 5.643B 10.47% | 5.319B 12.52% | 4.387B 7.55% |
| EBIT Q2Q % growth | 4.541B 34.59% | 3.838B 61.19% | 3.9B 54.88% | 3.024B 43.18% | 5.126B 12.88% | 4.361B 13.63% | 4.225B 8.33% | 3.45B 14.09% | 5.687B 10.94% | 4.894B 12.22% | 4.722B 11.76% | 3.883B 12.55% |
All data in USD
33 analysts have analysed CVS and the average price target is 95.66 USD. This implies a price increase of 14.85% is expected in the next year compared to the current price of 83.29.
CVS HEALTH CORP (CVS) will report earnings on 2026-05-06, before the market open.
The consensus EPS estimate for the next earnings of CVS HEALTH CORP (CVS) is 2.23 USD and the consensus revenue estimate is 96.15B USD.
The number of analysts covering CVS HEALTH CORP (CVS) is 33.